Kayne Anderson Rudnick Investment Management LLC trimmed its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 3.5% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 81,748 shares of the company's stock after selling 2,987 shares during the period. Kayne Anderson Rudnick Investment Management LLC's holdings in Eli Lilly and Company were worth $63,110,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Principal Financial Group Inc. increased its stake in shares of Eli Lilly and Company by 5.3% in the third quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company's stock worth $1,070,698,000 after purchasing an additional 60,306 shares in the last quarter. Invst LLC boosted its holdings in Eli Lilly and Company by 3.5% in the third quarter. Invst LLC now owns 5,552 shares of the company's stock valued at $4,918,000 after acquiring an additional 189 shares in the last quarter. McIlrath & Eck LLC raised its holdings in Eli Lilly and Company by 3.4% in the third quarter. McIlrath & Eck LLC now owns 481 shares of the company's stock worth $426,000 after purchasing an additional 16 shares in the last quarter. Virtu Financial LLC grew its stake in shares of Eli Lilly and Company by 111.7% in the 3rd quarter. Virtu Financial LLC now owns 6,531 shares of the company's stock worth $5,786,000 after buying an additional 3,446 shares during the last quarter. Finally, SOA Wealth Advisors LLC. grew its holdings in shares of Eli Lilly and Company by 2.4% during the third quarter. SOA Wealth Advisors LLC. now owns 864 shares of the company's stock valued at $766,000 after buying an additional 20 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.
Insider Activity
In related news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. This trade represents a 14.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.13% of the company's stock.
Eli Lilly and Company Stock Up 0.4 %
Shares of LLY traded up $3.03 during trading hours on Wednesday, reaching $830.57. The company's stock had a trading volume of 2,712,888 shares, compared to its average volume of 3,432,615. The company has a 50 day moving average of $827.10 and a two-hundred day moving average of $818.99. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The firm has a market cap of $787.52 billion, a price-to-earnings ratio of 70.93, a P/E/G ratio of 1.40 and a beta of 0.51.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. As a group, research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of analysts have commented on LLY shares. Leerink Partners set a $950.00 price target on Eli Lilly and Company in a research report on Friday, January 17th. Guggenheim cut their price target on Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating for the company in a report on Monday, April 14th. Wells Fargo & Company lifted their price objective on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. StockNews.com upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Friday, February 7th. Finally, Truist Financial upped their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. Two research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $1,017.00.
Check Out Our Latest Analysis on LLY
Eli Lilly and Company Profile
(
Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Featured Articles
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
